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Tracking Cell Therapy
Bioluminescence Lighting the Way*
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MCell-based therapies involving various types of stem
cells, pancreatic -cell islets, and bone marrow–
derived mononuclear cells (MNCs), among others,
are thought to have great potential as treatments for
a number of diseases, such as cancer, heart disease,
and diabetes. Peripheral artery disease is caused by
reduced blood flow to the limbs in arteries that have
become occluded by atherosclerotic plaques. De-
spite approaches such as stent emplacement or
vascular bypasses, a number of patients suffering
from peripheral artery disease do not recover and
See page 46
may have to undergo amputation (1). Due to the
lack of an effective treatment and the dire outcomes,
therapeutic angiogenesis using gene therapy ap-
proaches were explored and offered some potential
for rescuing ischemic limbs. However, after prom-
ising pre-clinical experiments, most clinical trials
failed. Most recently, a large trial of fibroblast
growth factor gene transfer did not alter the out-
come of keeping patients amputation-free (2). MNC
transplantation has been proposed as an alternative
therapy for sufferers of this disease due to the roles of
these cells identified in the natural response to ische-
mia (3). In addition, the MNCs of peripheral artery
disease sufferers are relatively few in number and
have been shown to function poorly (4), further
motivating MNC transplantation. The results of
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isease have been positive (1), motivating the use of
maging-based methods of cell tracking to facilitate
ptimization of MNC therapeutic strategies.
he development of cell tracking. Soon after cell-
ased therapies were proposed, it was recognized
hat tracking the transplanted cells via imaging
ould be highly valuable for technique optimiza-
ion. Cell tracking is often enabled by labeling the
onor cells with a diagnostically active substance,
uch as iron oxides for magnetic resonance imaging
5), indium-111 for single-photon emission com-
uted tomography (6), or quantum dots for fluo-
escence imaging techniques (7). Cell tracking of-
ers the possibility to determine the site of injection
f the cells, their migration, and, it was thought, the
esidence time of cells in the diseased tissue. How-
ver, the interpretation of cell tracking images has
een hampered by the fact that when the trans-
lanted cells die, macrophages or other neighboring
ells often take up the labeling material and the
ignal remains in the tissue, yielding a false-positive
esult that the transplanted cells are still resident in
he tissue (8).
ioluminescence in cell tracking. In order to address
he issue of false-positive signals arising from the
se of exogenous labels, some have turned to
ransplanting bioluminescent cells in order to mea-
ure viability (9). The methodology to make the
ells bioluminescent is normally to transfect the
ells of the donor ex vivo with viral constructs, then
ransplant them into the recipient. However, ques-
ions surround the effect of transfecting the donor
ells, such as whether perturbation of the cells’
enetic profile occurs and the impact of injecting
he recipient with viral material. In this issue of
JACC, van der Bogt et al. (10) report the use of
NCs from donor mice that constitutively express
oth luciferase and green fluorescent protein
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57(GFP), therefore avoiding some of the issues sur-
rounding the use of viruses or other gene transfer
techniques.
The authors transplanted MNCs into wild-type
mice of the same background that had undergone
unilateral femoral artery ligation via electrocoagu-
lation. In vitro experiments had confirmed the
extracted cells to express luciferase and GFP.
Strong signals were seen in the first few days
post-injection in the wounded leg from in vivo
bioluminescence measurements, when the MNCs
were injected intramuscularly. By the 13th day
post-injection, however, the majority of the trans-
planted MNCs had died, and essentially all MNCs
had died by 27 days. This result was confirmed by
immunohistological staining for GFP, when very
few MNCs were found in sections of the injured
muscle. Laser Doppler perfusion imaging of the
mouse paws was used as a measure of recovery of
blood flow. The cell treatments did not result in a
significantly faster or more substantial recovery than
control, with blood flow returning to pre-ligation
levels after 14 days. Histological detection of the
number of collateral arteries confirmed that there
were no therapeutic advantages derived from the
MNCs.
In addition to intramuscular injection, MNCs
were injected intravascularly to determine the effect
of different injection routes. Bioluminescence im-
aging showed the MNCs in this case to home to
several sites: the wounded leg, liver, spleen, and
bone marrow. In this experiment, it was also the
case that the blood flow recovery in the paws was
unaffected by the MNC treatment. The cell track-
ing imaging results reported seem to correspond
with the therapeutic measurements—that is, the
poor MNC survival observed from bioluminescence
imaging resulted in no improvement in blood flow
recovery compared with controls. This demon-
strates the potential of bioluminescence-based
tracking for optimization or screening of cell ther-
apies.
That no therapeutic effect of MNC transplanta-et al. Effect of fibroblast growth ment: mechanismsNevertheless, it is important to note that the model
used in this study was an acute injury model, as
opposed to the chronic state of peripheral artery
disease for which this therapy has been proposed.
The MNCs of patients with advanced atheroscle-
rotic peripheral artery disease have been shown to
have reduced ability to regenerate blood flow (4),
which will not be the case for healthy young mice,
as shown by the recovery of blood flow in 14 days in
untreated mice. Nevertheless, this study points to
the need for strategies to optimize therapeutic
response, notably the need for methods to prolong
cell survival, such as coadministration of drugs.
Other routes to protocol optimization might be to
improve cell homing to the diseased tissue or to
identify or isolate subpopulations of cells that will
have enhanced therapeutic effect. However, if other
studies reveal similar findings, MNCs may have no
role in therapeutic angiogenesis.
The future for bioluminescence in cell tracking. The
esults reported by van der Bogt et al. (10) show
ioluminescence imaging to be a powerful tech-
ique for cell tracking in small animals such as
ice. Methods such as this, or reporter gene meth-
ds, to measure the viability of transplanted cells
ill be vital for the development of successful cell
herapies. It is unlikely, however, that biolumines-
ence will be translated to patients due to the poor
issue penetration of light and concerns surrounding
mmunogenicity of luciferase and injections of lu-
iferin (11). Cell tracking in patients will likely be
ursued with techniques that have much better
issue penetration, such as nuclear techniques or
agnetic resonance imaging, both of which have
lready been studied in patients (5). Nevertheless,
ioluminescence imaging will be invaluable in re-
ning cell therapy methodology in pre-clinical set-
ings before moving on to clinical trials.
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